The introduction of the reversible monoamine oxidase-A inhibitor moclobemid was a promising development of the MAO inhibitor principle in the treatment af major depression. The irreversible MAO inhibitors has severe interactions with a broad range of drugs and patients needs to be very alert regarding specific dietary components such as redwine, cheese and so on. In spite of investigations showing promising results and a very beneficial side effect profile, the drug is currently not much used. This presentation reviews the principal studies included the DUAG study on moclobemide and tries to explain the fate of moclobemid.